Table 2. Comparison on spirometry and airway hyperresponsiveness.
| Parameters | NAR (n=262) | AR (n=377) | Control (n=264) | P value* | P value† | P value‡ |
|---|---|---|---|---|---|---|
| FVC pred% | 94.24±12.27 | 93.35±12.33 | 91.49±10.81 | 0.07 | 0.07 | 0.35 |
| FEV1%pred | 93.77±11.72 | 94.34±11.53 | 94.48±9.71 | 0.88 | 0.46 | 0.52 |
| FEV1/FVC | 85.68±7.44 | 85.59±7.36 | 89.5±5.97 | <0.01^ | <0.01^ | 0.87 |
| MMEF pred% | 81.29±19.91 | 82.36±20.76 | 85.59±17.02 | 0.04^ | 0.01^ | 0.49 |
| MEF50 pred% | 84.84±20.76 | 86.72±22.27 | 88.43±17.82 | 0.3 | 0.05^ | 0.26 |
| MEF25 pred% | 82.92±28.67 | 83.59±28.43 | 92.73±25.98 | <0.01^ | <0.01^ | 0.77 |
| AHR (No., %) | 16, 6.1% | 46, 12.2% | 3, 1.1% | <0.05^ | <0.01^ | 0.01^ |
*, denoted the comparison between group AR and healthy subjects; †, denoted comparison between group NAR and healthy subjects; ‡, denoted the comparison between group NAR and group AR. Data with ^ indicated the between-group comparison with statistical significance. NAR, non-allergic rhinitis; AR, allergic rhinitis; MMEF, maximal mid-expiratory flow; MEF50%, mid-expiratory flow when 50% of FVC has been expired; MEF25%, mid-expiratory flow when 75% of FVC has been expired.